Research Analysts Set Expectations for STERIS Q3 Earnings

STERIS plc (NYSE:STE) – Investment analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for shares of STERIS in a research report issued to clients and investors on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.31 for the quarter, up from their previous estimate of $2.30. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s FY2025 earnings at $9.08 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.54 EPS, Q4 2026 earnings at $2.81 EPS, FY2026 earnings at $9.99 EPS, Q1 2027 earnings at $2.48 EPS, Q2 2027 earnings at $2.59 EPS, Q3 2027 earnings at $2.63 EPS and FY2027 earnings at $10.35 EPS.

Several other analysts have also recently issued reports on STE. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and upped their price target for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Stephens reaffirmed an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. JMP Securities reissued a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Monday, November 18th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Finally, StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $262.50.

STERIS Price Performance

STE stock opened at $217.25 on Thursday. The stock’s 50 day moving average is $211.60 and its two-hundred day moving average is $224.70. STERIS has a 52-week low of $197.82 and a 52-week high of $248.24. The company has a market capitalization of $21.44 billion, a PE ratio of 49.60 and a beta of 0.84. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same period last year, the business earned $2.03 EPS. The business’s revenue was up 7.3% on a year-over-year basis.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were given a dividend of $0.57 per share. The ex-dividend date was Tuesday, November 19th. This represents a $2.28 annualized dividend and a dividend yield of 1.05%. STERIS’s dividend payout ratio is presently 52.05%.

Insider Buying and Selling

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares in the company, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in STE. Ashton Thomas Securities LLC bought a new position in shares of STERIS during the 3rd quarter valued at about $25,000. Central Pacific Bank Trust Division acquired a new position in shares of STERIS in the 3rd quarter worth $28,000. Quarry LP acquired a new stake in shares of STERIS during the third quarter worth $67,000. Asset Dedication LLC lifted its holdings in shares of STERIS by 54.8% during the third quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock valued at $71,000 after purchasing an additional 103 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of STERIS in the 4th quarter valued at $78,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.